Lode, Holger N. http://orcid.org/0000-0002-1201-208X
Ehlert, Karoline
Huber, Stephanie
Troschke-Meurer, Sascha
Siebert, Nikolai
Zumpe, Maxi
Loibner, Hans
Ladenstein, Ruth http://orcid.org/0000-0001-6548-3873
Article History
Received: 5 May 2023
Revised: 21 September 2023
Accepted: 28 September 2023
First Online: 10 October 2023
Competing interests
: RL and H Lode acted as consultants for Apeiron and EUSA Pharma for the clinical development of dinutuximab beta. H Lode participated in advisory boards organized by EUSA Pharma. H Loibner was CEO of Apeiron until July 2018. The remaining authors declare no competing interests.
: The study was conducted in compliance with Good Clinical Practice guidelines and in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of the University Medicine of Greifswald, Germany, and the Paul-Ehrlich Institute in Langen, Germany. All patients or their parents/guardians provided written, informed consent before study entry.
: Not applicable.